Previously recorded as Intelligent Bio-Systems, Inc. (to 2016)
Recorded as renamed to Qiagen Sciences, LLC (2018)
1 patent currently held
49 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2029. from the record
Of the 49 now held by other companies, 39 name Isoplexis Corporation as their current owner, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Mar 2029
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Nov 2028 · Medium confidence
The most cited patent in this portfolio, cited by 165 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2028.
now held by Isoplexis Corporation
Also notable
Ends Nov 2036 · High confidence
Cited by 22 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
now held by Isoplexis Corporation
Also notable
Ends Aug 2030 · High confidence
Cited by 60 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
now held by Isoplexis Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 12, 2027The maintenance fee for Methods And Compositions For Incorporating Nucleotides (US 10,472,382) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Aug 23 US 11,421,264 Thiol-Containing Cleave Reagents and Oxidative Wash · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods And Compositions For Incorporating Nucleotides | 1 in force | to Mar 2029 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,472,382 | Methods And Compositions For Incorporating Nucleotides In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 49 patents in force now held by others · 10 patents ended · 3 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
8 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
8 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.